ACF Bioservice has completed construction on its dedicated CGMP-compliant 3,400 square foot facility for gene and cell therapy product testing. ACF Bioservices develops quantitative cell-based in vitro potency assays to support FDA-mandated product release requirements. These potency assays range from relatively simple protocols to more complex and elaborate designs that determine the mechanism of action of a gene therapy product. “The dedicated cGMP facility is a natural extension o...